ACADIA PHARMACEUTICALS INC (ACAD)
Health Care · Specialty pharmaceuticals / Central nervous system disorders · NASDAQ
ACADIA Pharmaceuticals commercializes novel treatments for serious psychiatric and neurodevelopmental disorders including Parkinson's psychosis and Rett syndrome.
What ACADIA PHARMACEUTICALS INC does
ACADIA Pharmaceuticals develops and commercializes innovative medicines focused on treating psychiatric, neurological, and neurodevelopmental disorders. The company has two FDA-approved products: NUPLAZID (pimavanserin) for psychosis associated with Parkinson's disease and DAYBUE (trofinetide) for Rett syndrome. ACADIA is leveraging its portfolio to address significant unmet medical needs in patient populations with limited treatment options.
Themes: ["psychiatric disorders / neuropsychiatry","Rett syndrome / neurodevelopmental disorders","Parkinson's disease treatment","rare diseases / orphan indications"]
Fundamentals
- Price$26.41 as of 2026-07-09 close
- Market cap$4.5B as of 2026-07-10
- 1-year return+22.4% as of 2026-07-09 close
- P/E11.87 as of 2026-07-10
- Net margin+34.3% as of 2026-07-10
- Gross margin+91.5% as of 2026-07-10
- ROE+35.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-13.6% as of 2026-07-10
- Revenue CAGR (3y)+27.5% SEC XBRL
- Beta0.86 as of 2026-07-10
Key risks (from latest filing)
["NUPLAZID and DAYBUE commercialization success is dependent on physician adoption, patient acceptance, reimbursement coverage, and clinical outcomes that may differ from trial results in real-world settings","Regulatory risk including potential FDA label changes, boxed warnings, or market withdrawal based on new clinical data or post-approval studies","Market acceptance risk if products do not demonstrate sufficient benefits over standard of care or if negative side effects or patient experiences emerge"]
Competitors & peers
- Janssen Pharmaceuticals (part of J&J)
- Lundbeck
- Eli Lilly (LLY)
- Sage Therapeutics
- Biohaven Pharmaceutical
- REATA Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.